Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. Approval stipulates use of the combination, with or without bevacizumab, in adults...

FDA Clears PD-L1 Test to Guide Keytruda Use in Ovarian Cancer

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda.

FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer

The FDA approved IV and subcutaneous pembrolizumab with paclitaxel with or without bevacizumab for patients with platinum-resistant ovarian cancers.

FDA Approves Pembrolizumab/Chemo in Platinum-Resistant GYN Indications

Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.

Pembrolizumab Combination FDA-Approved for Ovarian Cancer

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.